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The extracellular matrix (ECM) of articular cartilage is comprised of complex networks of proteins and
glycoproteins, all of which are expressed by its resident cell, the chondrocyte. Cartilage is a unique tissue
given its complexity and ability to resist repeated load and deformation. The mechanisms by which
articular cartilage maintains its integrity throughout our lifetime is not fully understood, however there
are numerous regulatory pathways known to govern ECM turnover in response to mechanical stimuli. To
further our understanding of this ﬁeld, we envision that proteomic analysis of the secretome will provide
information on how the chondrocyte remodels the surrounding ECM in response to load, in addition to
providing information on the metabolic state of the cell. In this review, we attempt to summarize the
recent mass spectrometry-based proteomic discoveries in healthy and diseased cartilage and chon-
drocytes, to facilitate the discovery of novel biomarkers linked to degenerative pathologies, such as
osteoarthritis (OA).
© 2017 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
To gain a deeper understanding of the mechanisms that drive
osteoarthritis (OA), it is important to appreciate the underlying
biology of healthy and diseased joint tissues. Of interest is the
pathophysiology of articular cartilage, and the processes that. Sanchez, Bone and Cartilage
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2017), http://dx.doi.org/10.10govern synthesis and organisation of extracellular matrix (ECM)
components secreted by chondrocytes into the pericellular milieu.
The chondrocyte is the unique resident cell of articular cartilage
and thus solely responsible for ECM composition and regulation.
Chondrocyte metabolism is inﬂuenced by its micro-environment,
and in return inﬂuences ECM composition, organization and ulti-
mately the mechanical resilience of cartilage1e3. As such, chon-
drocytes play a key role in ECM remodelling in physiological and
pathological conditions4.
It is commonly established that healthy articular chondrocytes
change into different phenotypes as OA develops and progresses:
(i) A catabolic phenotype develops, associated with an increase
in proteolytic enzymes and reactive oxygen/nitrogen species,td. All rights reserved.
retome: a source of novel insights and exploratory biomarkers of
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kines, tumour necrosis factor (TNF)-a and interleukin (IL)-1b,
leading to further ECM degradation.
(ii) An anabolic phenotype emerges that is associated with
regeneration of the ECM, including increased collagen type II
and proteoglycan expression regulated by growth factors
(transforming growth factor (TGF)-b, bone morphogenetic
protein (BMP)s and insulin growth factor (IGF)-I), expressed
either by the surrounding joint tissue or by the chondrocytes
themselves.
(iii) A hypertrophic phenotype develops, manifesting in expres-
sion of type X collagen and induction of apoptosis, ultimately
resulting in osteophyte formation.
(iv) A ﬁbroblastic-like phenotype with an increased number of
dedifferentiated chondrocyte and expression of type I
collagen.
(v) Lastly, a chondroblastic phenotype emerges with expression
of foetal type IIA collagen, type III collagen and early/late
differentiation markers5.
The speciﬁc phenotype that any individual chondrocyte ex-
hibits is dependent on the zone in which the chondrocyte is sit-
uated and the stage of OA progression. In the upper zone, cellular
proliferation and hypertrophy are observed, whereas the mid and
deep zones display increased expression of type II collagen6. As OA
progresses, cartilage is lost and chondrocytes undergo senescence,
due to a combination of replicative exhaustion and oxidative
stress7.
Eventually, chondrocytes will undergo apoptosis, and the
articular cartilage will be destroyed. The ultimate goal of mass
spectrometry-based proteomics strategies is the identiﬁcation of a
speciﬁc tissue-derived secretome that is unique to the diseased
chondrocyte and surrounding ECM and is able to distinguish be-
tween healthy and diseased cartilage.
Because protein expression is dependent on environmental
conditions, the secretome is highly dynamic in composition and
turnover. In 2010, Agrawal et al. suggested deﬁning the secretome
as “the global group of secreted proteins into the extracellular
space by a cell, tissue, organ, or organism at any given time and
conditions through known and unknown secretory mechanisms
involving constitutive and regulated secretory organelles”8. In this
narrative review, we only considered the chondrocyte (or carti-
lage) as the source of secreted proteins, which have been uncov-
ered by state-of-the-art mass spectrometry-based proteomics
techniques.
Proteomic techniques include different methods, all relying on
the separation of proteins and their further analysis using either
gel-based (Two-dimensional electrophoresis) or gel-free methods.
Protein separation methods are coupled to a mass spectrometer for
identiﬁcation of sequence by mass spectrometry9,10. In differential
analysis, the peptides may be marked with stable isotope at various
stages of the analysis process, or Label-free methods could be
performed. Several modes of analysis are available in mass spec-
trometry10. They differ markedly by the ionization source of the
sample. The main sources used in proteomic analysis are matrix-
assisted laser desorption/ionization (MALDI) and surface-
enhancer laser desorption/ionization (SELDI)10,11. These tech-
niques allow a soft ionization of molecules without excessive
fragmentation9,11.
More than the total tissue protein extract, it is expected that
well-deﬁned protein fractions such as the secretome could be a
source of novel OA biomarkers, with the potential to predict disease
severity and monitor progression.Please cite this article in press as: Sanchez C, et al., Chondrocyte sec
osteoarthritis, Osteoarthritis and Cartilage (2017), http://dx.doi.org/10.10Materials and methods
A literature search was performed in Pubmed/Medline and
Scopus, identifying articles published between January 2004 and
March 2016. Keywords used in ‘Any ﬁelds’ were; (chondrocyte OR
cartilage) AND secretome (19 relevant papers out of 38 found), or
(chondrocyte OR cartilage) AND (proteomic ORmass spectrometry)
(65 articles relevant papers out of 290 found). Only results from
mass spectrometry-based studies were included in this article. The
review has considered all species, even if the majority of studies
have been performed on human source of chondrocytes or carti-
lage. Only research articles published in English were included.
Supplementary ﬁles of all papers were analysed and included in
this review.
Chondrocyte secretome
Recent mass spectrometry-based proteomic studies have
identiﬁed several proteins which form the chondrocyte secre-
tome. In this part of the review, we focused on proteins identiﬁed
either directly in the secretome of cartilage explants12e20 or
chondrocytes cultures18,21e31), both of which are listed in Table I
and illustrated in Fig. 1. We further complete this list with
proteins recently identiﬁed by proteomic analysis performed
directly on fresh chondrocytes or cartilage tissue32e36 (some-
times de-cellularized37) whereby different locations in the
joint were compared, or healthy joint tissues were compared
with OA tissues. The characteristics of all these studies are
summarized in Table II. Proteins have been classiﬁed in different
sections: ECM proteins, cytokines and growth factors, enzymes
and miscellaneous.
ECM proteins
As expected, the most abundant ECM proteins produced by
chondrocytes, and detected by proteomic analysis, are collagens
and proteoglycans, Table I. Thirteen collagens are found in the
chondrocytes secretome, of which type II, VI and XII are the most
abundant35. Collagen type XII is also known to interact with other
cartilage elements such as cartilage oligomeric matrix protein
(COMP), decorin and ﬁbromodulin38. Collagen type II and VI levels
are increased in the secretome of chondrocytes taken from the
medial condyle of patients with early OA (Mankin score 0e3),
compared with samples taken from patients with severe OA
(Mankin score 5e10)25.
Beside the collagens, other ECM proteins found in high abun-
dance in the chondrocyte secretome include; aggrecan, HPLN-1
(proteoglycan link protein), biglycan, COMP, ﬁbronectin, prolargin
(Proline-arginine-rich end leucine-rich repeat protein (PRELP)),
matrilin-3, cartilage acidic protein-1 (CRTAC1 or ASPIC), latent-
transforming growth factor beta-binding protein-1 (LTBP1), extra-
cellular matrix protein-1 (ECM-1), tenascin, lubricin and chitinase-
3-like protein 1 (CHI3L1), also known as YKL-40). CHI3L1was found
at lower levels in cartilage explants treated with IL-1b compared to
controls12. CHI3L1, is a biomarker of OA found in synovial ﬂuid and
serum39, and plays a role in tissue remodelling and inﬂammation.
The concentration of CHI3L1 in OA synovial ﬂuid positively corre-
lates with levels of matrix metalloproteinase (MMP)-1, MMP-3, IL-6
and IL-17.
IL-6 and IL-17 enhanced CHI3L1 production in human primary
chondrocyte cultures40 and CHI3L1 serum concentration positively
correlated with osteophyte size in OA patients41. This protein is
more abundant in knee compared to hip cartilage37 and in OAretome: a source of novel insights and exploratory biomarkers of
16/j.joca.2017.02.797
Table I
Summary of recent mass spectrometry-based proteomic studies carried out on human chondrocytes and cartilage to identify secretome components
ECM proteins Speciﬁcity OA vs normal With IL-1b References
Aggrecan core protein a 13,14,17,18,20,22,27,31e37
Asporin 32,34,37
Basement membrane-speciﬁc
heparin sulfate proteoglycan core protein (PGBM)
b 13,18,20,30
Biglycan b 13,14,17,18,20e22,27,30,32e37
Cartilage acidic protein-1 (CRTAC1, ASPIC) Speciﬁc chondrocyte marker b 13,16,22,26,33,35
Chitinase-3-like protein -1, -2 Tissue remodelling, inﬂammation b a 13,16,18,20e22,24,25,27,30,31,33,35,37
Chondroitin sulfate proteoglycan 4 (CSPG4) 18
Collagens type I, II, III, V, VI, VIII, IX, X,
XI, XII, XIV, XV, XVI
b 13,14,16,18,20,21,24e27,30e35,37
Cartilage oligomeric matrix protein (COMP) b 13,14,17,18,20,22,26,27,30e35,37
Decorin 12e14,18-21,27,30,32,34,35,37
Extracellular matrix protein-1 Negative regulator of bone mineralization,
promote angiogenesis,
inhibit MMP-9 activity
b 13,14,19,22,25,33
Fibrillin-1 18,22,25,27,30,35,37
Fibromodulin b 14,16e20,22,24,26,27,32e34,36
Fibronectin 14,16e18,20e22,26,27,30,32,34,35,37
Fibulin-1, -3, -4, -7 b 13,18,20e22,24,25,27,30,33,34
HPLN-1 (proteoglycan link protrein-1) Bind hyaluronic acid and aggrecan b b 13,14,18,19,22,24,27,32e35,37
Latent-transforming growth factor
beta-binding protein -1, -2 (LTBP1, 2)
Storage/activation TGF-b1,
structural role in ECM
13,20,26,27,30
Lubricin (proteoglycan-4) b 13,14,18,20e22,26,27,30,32e35,37
Lumican 13,14,16,18e22,24,25,27,30,32e35,37
Matrilin-2*, -3* 25,33e35,37
Matrix gla protein (MGP) b b 14,19,20,22,24,26,33e35,37
Mimecan (osteoglycin) b 13,18,22,27,30,32e34,37
Osteomodulin 18,22,30e32,34,37
Periostin b 13,22,35
Perlecan 34,37
Prolargin (PRELP) Bind type II collagen and perlecan 13,17,18,20,22,25,27,32e37
Syndecan-2, -4 b 19,21,35
Tenascin C, X b 13,18,20e22,30e32,34,35,37
Versican b 13,32,34,37
Cytokines and growth factors Speciﬁcity OA vs normal With IL-1b References
CCL2, -8, -14, -20 b 14,21,22,25,33
CSF-1 b 21,27
CTGF 16,18,20,22,24,30,31,33
CXCL1, -3, -5, -6 b 27,33
Cytokine receptor like factor 1 Decrease aggrecan and type II collagen synthesis 20,26
Gremlin-1 BMP antagonist, inhibit bone mineralization a 14,35
IGFBP-2, -3, -4, -5, -6, -7 IGFBP3b 12,18,20e22,24e27,30
IL-6, -8, -17b IL-17ba IL-6, -8b 14,19e21,25,27,33
Inhibin-bA/proinhibin-bA dimerise to form Activin A,
stimulating TIMP-1 production
b b 12,16,20,27
Leukocyte cell-derived chemotaxin 2 (LECT2) reduce IL-1b, IL-6 and other chemokines reduce IL-1b, IL-6 and
other chemokines79
b 18,33
Pleiotrophin (PTN) b 14,33
TGF-b2 22
Enzymes Speciﬁcity OA vs normal With IL-1b References
ADAMTS-1, -2, -4,-5 12,20,22,25
Angiogenin Deep layer e stimulate angiogenesis b 12,18,32e34,37
Carboxypeptidase E 14
Cathepsins (B, D, F, K, L1, Z) Bb 12,14,16,18,20e22,25,30,35
ENPP2 NTP pyrophosphatase, mineralization 22
Extracellular sulfatase Sulf1 Sulf2 14
HTRA1 (serine protease) Increase with TGF-b1 a 12,14,16,18,20,22,24,26,30,32,34,35,37
Lysozyme C b 12,14e16,20,32,34
MMPs (-1, -2, -3, -7, -10, -13, -14, -16) b b 12e16,18,20-25,27,30,31,34,35,37
Pappalysin-1 Metalloproteinase, cleave IGFBP-4,-5 22
Peroxiredoxin-1, -2, -4 Protecting cells from free-radical damage 2b 13,16,20,23,37
Phospholipase A2* b 12,13,32,34,35,37
Procollagen C-endopeptidase
enhancer (PCOLCE)-1, -2
Enhances procollagen C-proteinase activity.
C-terminal processed part of PCPE (CT-PCPE)
may have an metalloproteinase inhibitory activity.
Decrease with TGF-b1
b 12,14e16,18,20,22,24,26,30,33,34,37
Procollagen-lysine,
2-oxoglutarate 5-dioxygenase 1, 2
Collagen ﬁbre glycosylation b 22,31,58
Putative tryspin 6 (serine protease) 21
(continued on next page)
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Table I (continued )
Enzymes Speciﬁcity OA vs normal With IL-1b References
Pyruvate kinase [ 12,13,22
Serine protease 23 22
Sulfhydryl oxidase 12,22
Superoxide dismutase (SOD1, SOD2, SOD3) Protecting cells from free-radical damage SOD2a 12,14e16,22,23,25,31,32,34,35
Triosephosphate isomerase: Carbohydrate degradation b 12,14,16,20,22
Enzymatic inhibitors Speciﬁcity OA vs normal With IL-1b References
Antileukoproteinase Serine proteinase inhibitor 12,25
Cystatin C Cysteine proteinase inhibitor 18,21,22,26
Inter a Globulin inhibitor H2 HA processing 12
Inter a trypsin inhibitor HA processing,
Heavy chain H1 b 13
Heavy chain H4 18
SERPIN Serine protease inhibitors
A1: a1-antitrypsin 16,21,22,25,32,34
A2: anti-trypsin related protein 22
A3: a1-antichymotrypsin a 12,16,18,22,25,30,32e35
A5: Protein C inhibitor 12,22
E1: Plasminogen activator inhibitor 1 18,22,30,35
E2: Glia-derived nexin 14,20e22,32,35
F1: Pigment epithelium derived factor b 12,13,16,18,30
G1: Plasma protease C1 inhibitor 18,22,30
I2 a1 antiproteinase 2 14,15
TIMPs (-1, -2, -3, -4) TIMP-1 increase with TGF-b1 TIMP-1a 12,14e16,18,20e22,24e26,30,34,35,37
Tissue factor pathway inhibitor 1, 2 (TFPI) Serine protease inhibitors 26
Miscellaneous Speciﬁcity OA vs normal With IL-1b References
78 kDa glucose regulated protein 22,33e35
A1 acid glycoprotein 1, 2 Binding and modulation of
cytokines and growth factor, like IL-6 and TNF-a
b 13,34
ADAMTS-like 2 Bind to LTBP e no enzymatic function 25
Annexin A1, A2, A5, A1, A2b 14,18,20,22,30,35
Apolipoprotein AI, AII, D, E Bind lipids e proteoglycans and collagens interaction AI, AIIb
Da
13,18,19,30,34,35
CILP (1-1, 1-2, 2-1, 2-2) No intrinsic NTP pyrophopshatase activity but
IGF-1/TGF-b antagonists, increase with TGF-b1
b b 12,14,16,18,20,24,25,32,34,36,37
Chondroadherin Bind the cell to the type II collagen 13,14,16e18,20,25,32e35,37
Clusterin Chaperon e inhibit protein aggregation and apoptosis a 14e20,22,24,26,30,34,35,37
Complement C1q, C1r, C1s, C3, C8, C9,
factor B, factor D, factor H
B, C1r, C3 b 12e14,16,18,20-22,30,32,33,37
Emilin-1 Cell-ECM interaction 25,35,37
Ezrin-Radexin-Moesin-Transgelin Cytoskeletal related 13,20,22,27,32,35,80
Gelsolin Cytoskeletal related b 16,18,20,22,26,30e32,34,35,37,80
Lactadherin 15,18,20e22,30
Osteonectin (SPARC) ECM-cytokine interactions 14e16,18,22,24,25,30,33-35
Osteopontin Bind to mineral and inhibit mineralization b 13,20,34,37
Proﬁlin-1 Cytoskeletal related 18,20,27,30,80
S100A1 Calcium binding proteins, role in inﬂammation A1a
A8, A10b
13,19,21,22,25,27,32e35
Semaphorin 3A, 3C 22
Spondin -1 and -2 Cell adhesion-bind GAGs-Wnt agonist 12
Stanniocalcin 1, -2 18,26,30
Tetranectin Mineralization e bind to GAGs b 13,18,21,30
TGFBI (Transforming Growth Factor,
Beta-Induced)
Cell to type II collagen interactions,
endochondral bone formation
b 13,14,18,20e22,27,30,32e35,80
Thrombospondin-1, -3, -4 Cell-ECM interaction - angiogenesis 3b 1b 13,14,17e22,24,30,32,34,35,37
Vasorin may act as an inhibitor of TGF-b signalling 22
C. Sanchez et al. / Osteoarthritis and Cartilage xxx (2017) 1e114compared to healthy cartilage27 and is considered to be an early OA
biomarker in the Stenberg' proteomic study, which compared early
and severe OA secretomes25.
In comparison with normal cartilage explants, CRTAC1 is found
elevated in the OA cartilage secretome13. This protein is considered
a cartilage speciﬁc protein, appearing early during chondrocyte
differentiation of mesenchymal stem cells (MSCs)26. Expression of
CRTAC1 allows discrimination between human chondrocytes and
osteoblasts, or MSCs, in monolayer cell culture26,42. This protein is
therefore considered a good marker of chondrocytic differentiation
of MSCs.
LTBP1 also seems to be an important ECM protein secreted early
in the differentiation of MSCs to chondrocytes26. Beside its struc-
tural role in the ECM, this protein is involved in the storage and thePlease cite this article in press as: Sanchez C, et al., Chondrocyte sec
osteoarthritis, Osteoarthritis and Cartilage (2017), http://dx.doi.org/10.10activation of TGF-b1, and therefore may play an important role in
facilitating cartilage homeostasis.
ECM-1 is a protein involved in endochondral bone formation
serving as a negative regulator of bone mineralization43. It is able
to enhance the proliferation of endothelial cells during angio-
genesis44 and inhibit MMP-9 proteolytic activity45. Louridos et al.
observed that the level of ECM-1 secreted by cells originating
from damaged OA cartilage is 3-fold higher than that of healthy
cartilage13.
Periostin secretion from explants increases with cartilage
degradation13, and was only found in cultured OA chondrocytes35.
Expression of periostin was previously shown to be elevated in OA
cartilage compared to normal, and located in the pericellular ECM
close to damaged areas of cartilage46,47. Periostin is able to increaseretome: a source of novel insights and exploratory biomarkers of
16/j.joca.2017.02.797
Fig. 1. Schematic representation of the chondrocyte secretome, based on data from mass-spectrometry based proteomic studies. ADAMTS: A Disintegrin And Metalloproteinase
with Thrombospondin Motifs, Apo: apolipoprotein, BMP: Bone morphogenetic protein, CCL: Chemokine ligand, CHAD: Chondroadherin, ChM: chondromodulin, CILP: Cartilage
intermediate layer protein, CHI3L1: Chitinase-3-like protein 1, COMP: Cartilage oligomeric matrix protein, CRLF: Cytokine receptor-like factor, CRTAC: Cartilage acidic protein, CSF:
Macrophage colony-stimulating factor, CTGF: Connective tissue growth factor, Cx: connexin, CXCL: C-X-C motif chemokine ligand, ECM: extracellular matrix protein, ENPP:
Ectonucleotide pyrophosphatase/phosphodiesterase family member, EMI: emilin, HSPA5: 78 kDa glucose-regulated protein, HTRA: High-temperature requirement A serine
peptidase, IL: Interleukin, LTBP: Latent-transforming growth factor beta-binding protein, MGP: matrix gla protein, MMP: matrix metalloproteinase, PCOLCE: Procollagen C-
endopeptidase enhancer, PLOD: Procollagen-lysine,2-oxoglutarate 5-dioxygenase, PRELP: proline-arginine-rich end leucine-rich repeat protein, SERPIN: serine protease inhibitors,
SOD: superoxide dismutase, SPARC: Secreted protein acidic and rich in cysteine, TGFBI: Transforming growth factor-beta-induced protein ig-h3, TGF: transforming growth factor,
TIMP: tissue inhibitor of metalloproteinase, TNAP: tissue non-speciﬁc alkaline phosphatase, TSP: thrombospondin.
C. Sanchez et al. / Osteoarthritis and Cartilage xxx (2017) 1e11 5expression of IL-6, IL-8, MMP-1,-3,-13 and a disintegrin and met-
alloproteinase with thrombospondin motifs (ADAMTS)-4 by chon-
drocytes in vitro46,47. Fibronectin and ﬁbromodulin are secreted at
comparable levels by OA and normal chondrocytes, but fragmen-
tation of these ECM proteins is found to differ depending on
whether the cell is healthy or diseased36,48.
Cytokines and growth factors
Classical cytokines and chemokines like IL-6, IL-8, CCL8-20,
CXCL1-3-5-8, CSF-1 are detected by tandem mass spectrometry
only after an IL-1b stimulation of chondrocytes, cultured either in
explant or in monolayer12,14,19,22,27.
The IGFBP family is widely represented in chondrocyte secre-
tome by IGFBP-2,-3,-4,-5,-6 and -712,21,22,24e27. Expression of IGFBP-
3,-4,-6 and -7 is increased in early OA25. These proteins serve as aPlease cite this article in press as: Sanchez C, et al., Chondrocyte sec
osteoarthritis, Osteoarthritis and Cartilage (2017), http://dx.doi.org/10.10carrier protein for IGF-1 and modulate the availability of IGF-1 to
bind its receptor. Furthermore, IGFBP3 is known to induce chon-
drocyte apoptosis during OA49. In contrast IGFBP5 that has a posi-
tive role in cartilage anabolism, and inhibits enzymatic
degradation; in fact IGFBP5 promotes cartilage extracellular matrix
formation in vivo in the DMM OA rat model50.
Among growth factors detected in the chondrocyte secretome,
gremlin-1, chondromodulin and pleiotrophin are known to be
involved in hypertrophic differentiation regulation. Gremlin-1 is a
BMP antagonist presenting reduced secretion from OA chon-
drocytes compared to normal14,35, and plays an important role in
bone development by inhibiting bone formation51. Gremlin-1 is
therefore, potentially, a potent inhibitor of chondrocyte hypertro-
phy in cartilage. Chondromodulin is also important for chon-
drocytes stabilization, acting by inhibiting hypertrophic
differentiation, and is shown to be secreted only by superﬁciallyretome: a source of novel insights and exploratory biomarkers of
16/j.joca.2017.02.797
Table II
Characteristics of the reviewed studies
Study Method Secretome Chondrocyte culture Explant culture
Peffers et al. 201312 OA ± IL-1b X X
Lourido et al. 201413 Normal vs wound or unwound OA X X
Svala et al. 201514 Equin ± IL-1b X X
Williams et al. 201315 Equin ± IL-1b X X
Hermansson et al. 200416 OA only X X
Clutterbuck et al. 201117 Equin ± IL-1b X X
Peffers et al. 201620 Equin ± IL-1b X X
Polacek et al. 201018 OA monolayer vs explant culture X X X
Swan et al. 201319 Canine ± IL-1b X X
Calamia et al. 201221 Normal þ IL-1b X X
Calamia et al. 201422 OA ± chondroitine or glucosamine sulfate X X
Catterall et al. 200623 OA ± IL-1b X X
Riffault et al. 201524 OA ± TGF-b1 X X
Stenberg et al. 201325 Early OA vs late OA X X
Rocha et al. 201426 bMSCs chondrogenic differentiation X X
Lourido et al. 201527 OA or normal þ IL-1b X X
Taylor et al. 201528 Bovine P0 vs P2 chondrocytes X X
Haglund et al. 200829 Rat, þ/ LPS X X
Polacek et al., 2011a30 Chondrocytes vs MSCs X X
Polacek et al., 2011b31 Monolayer vs aggregate culture X X
Onnerfjord et al. 201232 Type of cartilage X
Ikeda et al. 201333 Normal vs OA hip X
Muller et al. 201434 Normal at superﬁcial vs intermediate vs deep layer X
Tsolis et al. 201535 Normal vs OA X
Cillero-Pastor et al. 201336 Normal vs OA from superﬁcial to deep layer with MALDI-IMS X
Gago-Fuentes et al. 201580 Cx43 complexes from normal vs OA chondrocytes X
Hsueh et al. 201537 Decellularized cartilage from normal vs OA,
knee vs hip and superﬁcial vs intermediate vs deep layer
X
C. Sanchez et al. / Osteoarthritis and Cartilage xxx (2017) 1e116located chondrocytes34. Pleiotrophin is a secreted heparin-binding
peptide expressed in mesodermal and neuroectodermal cells dur-
ing development, but rarely in adult tissues. Pleiotrophin is abun-
dant in foetal and juvenile cartilage, but not in mature.
Furthermore, pleiotrophin is re-expressed in chondrocytes in early
OA, and is involved in the clustering and proliferation of chon-
drocytes observed in the early stages of OA52. Pleiotrophin is an
inducer of hypertrophy during chondrogenic differentiation of
MSCs53 and is also a potent pro-angiogenesis factor.
Proteolytic enzymes and their regulators
Proteomic analysis of the chondrocyte secretome shows that the
most abundant family of enzymes secreted is theMMPs, along with
their endogenous inhibitors, the TIMPs. MMP-1 and 3, and TIMP-1,
are particularly abundant. TIMP-3 appears to be more abundant in
normal hip cartilage than knee, but MMP-1 is contrarily abundant
in normal knee cartilage37. According to these studies, MMP-13 was
only identiﬁed following IL-1b-stimulation15, or is at very low
levels without stimulation14. With the exception of MMP-213, MMP
protein levels do not vary substantially between normal and OA
chondrocytes, but all increase with IL-1b treatment. TIMP-1 and -2
levels are decreased in OA medial condyles25, and TIMP-1 is
increased with TGF-b1 stimulation24.
The other family of metalloproteinases expected to be found in
cartilage is the ADAMTSs. Although ADAMTSs were found in some
proteomic secretome studies12,22,25, they were not identiﬁed in all
studies; most likely due to varying extraction methods which can
eliminate ADAMTSs, along with the glycosaminoglycan (GAG) at-
tachments of proteoglycans15. ADAMTS'smay not be easily identiﬁed
in mass spectrometry-based proteomic studies also due their rela-
tively low abundance. Indeed, saturation of detectors with high
abundance ions, type of protease used in mass spectrometry based
studies (mainly trypsin) which may lead to non-identiﬁcation of
ionizedpeptides as theyare too small, too large or contain aminoacid
sequences less likely to be ‘seen’ following ion identiﬁcation. PositivePlease cite this article in press as: Sanchez C, et al., Chondrocyte sec
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formed usingOA chondrocytes or OA cartilage explant culture12,22,25.
A recent study published by Svala, showed that peptides cleaved
from aggrecan, following IL-1b stimulation in chondrocytes, were
generatedbyMMPs, but not byADAMTSs14. Thisﬁnding conﬁrms the
importance ofMMPs in cartilage ECMbreakdownmediated by IL-1b.
However, the fragmentation patterns, and differential distribution
between cartilage and synovial ﬂuid, are consistent with the exis-
tence of at least two proteolytic pathways for aggrecan degradation
in human OA, generating both 342FFGV- and 374ARGS-fragments54.
Both the MMP-generated N-terminus of 342FFGV-fragment and the
aggrecanase 374ARGS-fragment are found in theOAsynovialﬂuid, but
only the 342FFGV is found in cartilage tissue itself54.
A further intriguing proteomic studywas conducted to elucidate
the target of MMPs and ADAMTSs in articular cartilage20,55. Human
articular cartilage55 or crude equine cartilage proteoglycan
extract20 was digested by the addition of exogenous metal-
loproteases, including MMP-2, -3, -8, -9, -12, and -13 and the
aggrecanases ADAMTS-4 and ADAMTS-5. Digestion products were
identiﬁed by proteomic methods, and complete sequences of
generated peptides were determined. A wide variety of peptides,
originating from collagen types I, II, and III, biglycan, prolargin,
ﬁbromodulin, ﬁbronectin, decorin, COMP, cartilage intermediate-
layer protein, megakaryocyte-stimulating factor, clusterin, mim-
ecan, aggrecan, and lumican, were obtained20,55. MMP-2 was the
most active protease used in the study, and the aggrecanases were
the least active in generating peptides from cartilage digestion. The
aggrecanases showed a preference for cleaving proteoglycan-
containing proteins. However, all of the proteases cleaved many
types of cartilage ECM proteins55. Interestingly, IL-1b treatment
generated many COMP neopeptides14,20. Some biglycan and COMP
neopeptides were identiﬁed as being generated by ADAMTS-4 or
MMP-3 and even increased by IL-1b concerning COMP20 are found
increased in the horse OA synovial ﬂuid compared to normal one,
i.e., 191CIEMGGNPL for biglycan and 149CEACPPGYSGPTHEGVGM166
and 87AQCAPGSCFPGVACTQ102 for COMP56.retome: a source of novel insights and exploratory biomarkers of
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one of the most abundant secreted protein by chondrocytes. This
enzyme cleaves aggrecan, within the interglobular domain, in hu-
man cartilage57. Levels of HTRA1-generated aggrecan fragments,
containing the VQTV (356) neoepitope, were signiﬁcantly elevated
in OA cartilage compared with cartilage from healthy joints;
implicating HTRA1 as a critical protease involved in proteoglycan
turnover and cartilage degradation during degenerative joint dis-
ease57. Cleavage of aggrecan by HTRA1 was strongly enhanced by
HTRA1 agonists such as CPII, a C-terminal hexapeptide derived
from the C-propeptide of procollagen IIa157. HTRA1 is preferentially
localized in the deep layer of cartilage34 and increased during
chondrocyte differentiation of MSCs26, and by TGF-b1 stimula-
tion24. HTRA1 is reduced 4-fold in OA vs normal chondrocytes35,
with no difference detected between OA and normal decellularized
cartilage37.
Procollagen C-endopeptidase enhancer (PCOLCE)-1, and 2, are
proteins which enhance procollagen C-proteinase activity,
commonly identiﬁed in many proteomic studies. Furthermore, the
C-terminal processed domain of PCPE (CT-PCPE) may have metal-
loproteinase inhibitory activity. PCOLCE1 is increased during
chondrocyte differentiation of MSCs26 and in OA cartilage37, but is
decreased with IL-1b14,15 and with TGF-b124.
Other enzymes that could be important in the regulation of
collagen metabolism are the procollagen-lysine, 2-oxoglutarate 5-
dioxygenases 1 and 2. Expression of these enzymes is increased
upon IL-1b stimulation22,58, and they could be responsible for an
over glycosylation of collagen ﬁbrils, observed in OA, which de-
creases ﬁbril ﬂexibility58.
Another set of enzymes found to be greatly increased in the OA
chondrocyte secretome are the lysosomal enzymes, including ca-
thepsins, phospholipases, peroxiredoxins, ovochymase-136,37. In
fact, cathepsin activity based probes have detected increased
cathepsin B activity in blood and synovial ﬂuid of early OA patients,
while cathepsin S was associated with RA59.
Other enzyme families detected in chondrocyte secretome
comprise of SERPINs, superoxide dismutases (SODs), tri-
osephosphate isomerase and lysozyme C enzymes. These are
modulated by IL-1b, but are not signiﬁcantly modiﬁed with the
disease, except SERPINA3. SERPINA3, also known as a1-
antichymotrypsin, is mainly located in the superﬁcial layer of the
articular cartilage34 and is decreased during OA35.
Miscellaneous secretome proteins
The chondrocyte secretome contains many proteins involved in
cellular regulatory pathways, cellecell or cell-ECM interactions,
including chaperons, alarmins, apolipoproteins and chondrocalcin.
Chondrocalcin is the C-terminal of type II collagen, associated with
the calciﬁcation of cartilage ECM.
Gelsolin, clusterin and transforming growth factor-beta-
induced protein ig-h3 (TGFВІ) appeared in nearly all secretome
studies and are one of the most highly secreted proteins by
chondrocytes14e19,22,24,26,30,34,35,37. Gelsolin is increased in OA
compared to normal chondrocytes35,37. Clusterin inhibits protein
aggregation and apoptosis. This protein is detected more in
healthy than osteoarthritic cartilage37. TGFBI is known to be
involved in the interaction of the cell with type II collagen, and
plays an important role in endochondral bone formation. Indeed,
this factor is an inhibitor of mineralization. It was found to be
highly secreted by OA chondrocytes, compared to normal chon-
drocytes13, and present at a greater abundance in hip OA than
healthy cartilage33.
Osteonectin is involved in ECM-cytokine interactions. Similar to
osteopontin, osteonectin is highly secreted in deep layerPlease cite this article in press as: Sanchez C, et al., Chondrocyte sec
osteoarthritis, Osteoarthritis and Cartilage (2017), http://dx.doi.org/10.10chondrocytes34, and found to be increased in the secretome of
medial condylar early OA cartilage16,25,27. TGF-b1 decreases the
production of osteonectin24.
Finally, thrombospondin-1,-3,-4 are all involved in cell-ECM
interaction and angiogenesis, and are also secreted by chon-
drocytes13,14,17,19,21,24,32,34,35,37. They are more abundant in the su-
perﬁcial layer of cartilage34. Thrombospondin-3 is increased in OA
compared to normal chondrocyte secretomes13, and
thrombospondin-1 is increased with IL-1b treatment19.
Discussion
The “omics” approach is a general exploratory approach used to
investigate alterations in an enormous number of genes, transcripts,
proteins, lipids and metabolites, in healthy vs diseased tissues. The
challenge of using this approach is to identify those candidates that
are speciﬁcally involved in the disease process. Themost commonly
used omics approaches include genomics, proteomics, lipidomics,
metabolomics and transcriptomics. Such “omics” technologies
applied to serum or urine samples have uncovered numerous new
biomarkers, which are ubiquitous molecules in most cases. There-
fore, it would be beneﬁcial to reﬁne “omics” technologies specif-
ically to joint tissues (cartilage, bone, meniscus, synovial
membrane) and compare “omics” proﬁles of the various articular
tissues taken at different stages of evolution and correlate those
amongst the various diseased tissues for the joint. In particular, the
secretomeof chondrocytes is of great interest because this approach
provides a range of biomarkers reﬂecting the metabolic changes
occurring in themain tissue affected byOA. Further, by investigating
the chondrocyte secretome we increase the chance of identifying a
circulating biomarker speciﬁc to disease, even speciﬁc to aparticular
joint. In this paper, we have reviewed and summarized data pro-
duced by proteomic analysis of cartilage or chondrocyte culture
supernatants. Interestingly, some proteins have been found to in-
crease in the secretome of OA explants or OA chondrocytes, while
few were found decreased in comparison with normal secretome.
Among these, some have been found in synovial ﬂuid, serum or
urine and proposed as potential biomarkers. For example, type II
collagen60e64, aggrecan63,65,66, lumican67,68, COMP64,66, gelso-
lin67,69, ﬁbulin-370, mimecan69, periostin13,71,72, SERPINs67,70,73 are
found in these ﬂuids in their native form, but also post-
transcriptionally modiﬁed and/or fragmented. Some of these pro-
teins or protein fragments have demonstrated to be burden of dis-
ease, prognostic, and efﬁcacy of intervention or diagnostic soluble
biomarkers, according the Burden of Disease, Investigative, Prog-
nostic, Efﬁcacy of Intervention and Diagnostic (BIPEDS) criteria.
Some peptides generated during type II collagen degradation have
been particularly well investigated, because type II collagen is the
most speciﬁc protein of cartilage. Further, their concentration ap-
pears to be modiﬁed in joint disease. As previously mentioned,
many aggrecan neoepitopes are found in cartilage tissue, but those
generated by aggrecanases are largely released from cartilage and
found in blood circulation, while the majority of fragments gener-
ated by MMPs remain entrapped in the tissue54.
Although the proteomic approach is a good approach to study
secretome, there are some limitations associated with this method.
Quantitative assessment of proteins secretome using these prote-
omic techniques remain hazardous, because the method promotes
the quantiﬁcation of some proteins relative to their solubility,
binding to other components, their size, length, amino acid
sequence and also their post-translational modiﬁcations. Small
proteins, like cytokines, give few peptides after tryspinisation, and
because at least 2 peptides are needed to assure the identiﬁcation
of the protein, they are probably excluded from the ﬁnal
observation.retome: a source of novel insights and exploratory biomarkers of
16/j.joca.2017.02.797
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For example, there is to date few studies really dedicated and
designed to investigate the dynamic kinetics of cartilage meta-
bolism during OA disease. Most of the studies compare healthy and
end-stage OA chondrocyte secretome, with the aim to discover new
proteins secreted by the chondrocytes. For example, CRTAC1,
HTRA1, PCOLCE, LTBP1, ECM-1, gremlin-1, clusterin, have been
identiﬁed using this approach and nowneedmore investigations to
decipher their role in chondrocyte metabolism during OA
pathogenesis.
The abundance of diverse models used in these proteomics
studies also make them difﬁcult to interpret. In monolayer, chon-
drocytes certainly have a different secretome than in their native
3D environment31. In explant culture, the majority of the newly
synthesized proteins remains entrapped in the ECM and only
degraded products are released into the supernatant18. Mechanical
stimulation of the explant should be performed to mimic the
physiological ﬂow and help the protein to be released from tissue.
Posttranslational modiﬁcations like glycosylation, glycation,
nitration are seldom investigated. A metabolomics approach would
allow to investigate these changes and to complete knowledge
coming from proteomic.
Many supposed cytoplasmic proteins are found in the chon-
drocyte secretome using proteomic technics. This ﬁnding seems
surprising but can be explained by the secretion of ECM-derived
vesicles by chondrocytes. Articular cartilage vesicles (ACVs) are
50e150 nm membrane-bound extracellular organelles found in
normal articular cartilage. They were initially characterized in
reference to their role in pathologic mineralization in cartilage in
studies which mirrored those of matrix vesicles derived from
growth plate cartilage and other normally mineralizing tissues.
ACVs contain enzymes, ions and substrates necessary for mineral
formation74. The presence of these ACVs explain why cytoplasmic/
membrane proteins, such as annexins, have been identiﬁed in the
secretome of the chondrocytes. Transmembrane proteins can also
be cleaved leading to the release in the extracellular space of
extracellular part of the protein, which is the case of syndecans75.
Another explanation at the presence of membrane proteins in the
secretome is the presence of apoptotic cells, mainly during OA76e78.
Loss of cell integrity during apoptosis further contribute to
emerging proteins and pathway end-products in synovium and
other bodily ﬂuids, potentially giving rise to several biomarkers
whichmay predict the susceptibility of an individual to develop OA.
Pro-inﬂammatory cytokines, prostaglandins and reactive oxy-
gen species (ROS) activate the normally quiescent articular chon-
drocytes and induce them to undergo a phenotypic shift through a
phenomenon recently described as “chondrosenescence”, leading
to further disruption of homeostasis and metabolism in cartilage7.
Effectively, chondrosenescence is the term that describes the age-
dependent deterioration of chondrocyte function and how it un-
dermines cartilage function in OA. Until now, this particular
phenotype has not yet been investigated by proteomic technics.
This should be added in the research agenda.
In conclusion, proteomic analysis of chondrocytes secretome is a
promising approach for detecting changes in chondrocyte meta-
bolism linked to OA diseases (Table I). This review listed the ad-
vantages and disadvantages of secretome investigation using the
proteomic methods. The main limitation is the lack of standardi-
zation of the culture protocols, while the main advantage is the
possibility to compare different environmental condition on the
secretome. We have also suggested some research perspectives,
including comparison of secretome at different disease stages.
Deﬁnitively, research on secretome using proteomic methods have
to be encouraged with the objectives to identify new biomarkers
reﬂecting chondrocyte metabolic changes in OA.Please cite this article in press as: Sanchez C, et al., Chondrocyte sec
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